Acasti Pharma, Inc. - (ACST): Price and Financial Metrics
ACST Price/Volume Stats
| Current price | $2.93 | 52-week high | $3.84 |
| Prev. close | $2.90 | 52-week low | $1.72 |
| Day low | $2.86 | Volume | 2,127 |
| Day high | $2.93 | Avg. volume | 25,973 |
| 50-day MA | $3.30 | Dividend yield | N/A |
| 200-day MA | $2.60 | Market Cap | 27.54M |
ACST Stock Price Chart Interactive Chart >
Acasti Pharma, Inc. - (ACST) Company Bio
Acasti Pharma Inc operates as pharmaceutical company. The Company develops drugs for cardiovascular diseases. Acasti offers omega-3 phospholipids a major component of cell membranes.
Latest ACST News From Around the Web
Below are the latest news stories about ACASTI PHARMA INC that investors may wish to consider to help them evaluate ACST as an investment opportunity.
Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?Just because a business does not make any money, does not mean that the stock will go down. For example, although... |
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of nimodipine being developed to address the high unmet medical needs for a rare disease, aneurysmal Subarachnoid Hemorrhage (aSAH), today announced that Chief Executive Officer Prashant Kohli will participate in the following investor and industry networking events in San Francisco, California during th |
Acasti Announces Second Quarter 2024 Financial Results and Business HighlightsAnnounced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 Completed $7.5 Million Private Placement Equity Financing led by ADAR1 Partners, LP, Providing Funding Well Beyond Anticipated Submission of GTX-104 New Drug Application (NDA) Highlighted the Potential of GTX-104 as New Treatment Standard for Aneurysmal Subarachnoid Hemorrhage (aSAH) in Key Opinion Leader Virtual WebinarPresented Poster on Pharmacokinetic Comparison of GTX-104 with Oral Nimodipine at 2023 |
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON TrialWith achievement of enrollment milestone, pivotal STRIVE-ON safety trial on track for potential NDA submission anticipated to occur in the first half of calendar 2025 Recently announced $7.5 million private placement financing extends projected cash runway to the first calendar quarter of 2026 PRINCETON, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that add |
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)Virtual Webinar to Take Place October 11, 2023 at 2:00pm ETPRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that it will host a virtual KOL event titled GTX-104: a potential new treatment standard for rare and life-threatening aS |
ACST Price Returns
| 1-mo | -13.82% |
| 3-mo | 14.90% |
| 6-mo | 22.08% |
| 1-year | 8.42% |
| 3-year | -88.48% |
| 5-year | -93.22% |
| YTD | 1.38% |
| 2023 | -3.86% |
| 2022 | -60.24% |
| 2021 | -51.54% |
| 2020 | -86.73% |
| 2019 | 195.18% |
Loading social stream, please wait...